---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-001181"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2021-08-10T23:59:59+00:00"
generated_at: "2026-06-29T16:40:49.681652+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Clearside reports Q2 2021 net loss $6.1M; OASIS Cohort 2 underway; XIPERE PDUFA Oct 30

## Summary
- Net loss of $6.1M ($0.11/share) vs $5.8M ($0.13/share) in Q2 2020.
- Revenue of $0.8M from partner licensing; cash $26.4M to fund ops into Q2 2022.
- OASIS Phase 1/2a wet AMD: Cohort 1 met safety endpoints; Cohort 2 enrollment (0.1 mg dose) underway.
- XIPERE NDA resubmission accepted; FDA PDUFA action date of October 30, 2021.

## SEC filing metadata
- accession: 0000950170-21-001181
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2021-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017021001181/0000950170-21-001181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017021001181/clsd-20210810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-001181
- JSON: https://secwatch.observer/filing/0000950170-21-001181.json
- Plain text: https://secwatch.observer/filing/0000950170-21-001181.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.